New York, NY (Press Release) – Despite new ther­a­pies, multiple myeloma remains incurable, causing most patients to ultimately develop drug resistance and succumb to the disease. The pursuit of drugs that inhibit cell cycle regulators, especially cyclin-dependent kinases (CDKs), has been an intense focus of research in cancer. A new study by researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has shown that targeting both CDK4 and ARK5, proteins responsible for maintaining energy bal­ance within the cell, was extremely effective in causing cell death in …

• The trial is a dose escalation study eval­u­ating safety and feasibility of T-cell Natural Killer Receptor NKG2D in patients with acute myeloid leukemia or mul­ti­ple myeloma
• No dose limiting toxicity re­ported of the last patient of the sec­ond dose level
• First patient of third dose level (10^7 cells) started cell processing

Mont-Saint-Guibert, Belgium (Press Release) – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and devel­op­ment of engi­neered cell ther­a­pies, with clin­i­cal pro­grams in cardio­vascular dis­ease and immuno-oncology, to­day an­nounced the com­ple­tion of the 21-day safety follow-up of the last patient en­rolled in the sec­ond dose level in the Phase I/IIa clin­i­cal trial eval­u­ating the safety and feasibility of its NKR-2 T-cell ther­apy using T-cells with NKG2D re­cep­tor in cancer patients suffer­ing from acute myeloid leukemia …

• Celgene has agreed to exercise its op­tion to ex­clu­sively license bb2121 under global stra­te­gic col­lab­o­ration
• bluebird bio to re­ceive $10 million op­tion exercise pay­ment from Celgene

Cambridge, MA (Press Release) – bluebird bio, Inc. (Nasdaq:BLUE), a clin­i­cal-stage com­pany com­mit­ted to devel­op­ing poten­tially trans­for­ma­tive gene ther­a­pies for severe ge­netic dis­eases and T cell-based immuno­therapies for cancer, an­nounced treat­ment of the first patient in a Phase 1 study of its prod­uct can­di­date bb2121 in patients with re­lapsed / re­frac­tory mul­ti­ple myeloma. bb2121 is a chi­meric an­ti­gen re­cep­tor T cell (CAR T) ther­apy targeting B cell maturation an­ti­gen (BCMA), and bluebird bio is devel­op­ing bb2121 in col­lab­o­ration with Celgene Corpo­ra­tion. bluebird bio also …

Announcement comes as recent clin­i­cal results reveal ixazomib sig­nif­i­cantly extends pro­gres­sion-free survival for patients with re­lapsed / refractory multiple myeloma

Oakville, ON (Press Release) – The New Drug Submission (NDS) for Takeda’s ixazomib has been accepted for priority review by Health Canada. Ixazomib is the first inves­ti­ga­tional oral pro­te­a­some inhibitor for the treat­ment of patients with re­lapsed and/or refractory multiple myeloma. If approved, ixazomib will be the first oral pro­te­a­some inhibitor avail­able in Canada, helping meet the urgent needs of patients living with multiple myeloma, a dev­as­tat­ing, relapsing and incurable rare cancer. With …

London (Press Release) – The best way to diagnose, treat and monitor myeloma – a type of blood cancer – has been set out in guidance published today by the National Institute for Health and Care Excellence (NICE). The NICE clin­i­cal guideline aims to help the NHS provide con­sis­tently excellent care for people over the age of 16 in England with myeloma.

Myeloma (also called multiple myeloma) is a relatively rare type of cancer; around 4800 people are diag­nosed with the disease each year in the UK making it the 17th most …

Positive opinion based on re­duc­tion in the risk of dis­ease pro­gres­sion or death with Empliciti in com­bi­na­tion with standard of care regi­men for mul­ti­ple myeloma dem­onstrated in ELOQUENT-2 study

Princeton, NJ (Press Release) – Bristol-Myers Squibb Com­pany (NYSE:BMY) and AbbVie (NYSE:ABBV) to­day an­nounced that the Com­mit­tee for Medicinal Products for Human Use (CHMP) of the Euro­pean Medicines Agency (EMA) has adopted a pos­i­tive opinion rec­om­mending that Empliciti (elo­tuzu­mab), an inves­ti­ga­tional immunostimulatory anti­body, be granted ap­prov­al for the treat­ment of mul­ti­ple myeloma as com­bi­na­tion ther­apy with Revlimid® (lena­lido­mide) and dexa­meth­a­sone in patients who have re­ceived at least one prior ther­apy. The appli­ca­tion now will be reviewed by the Euro­pean Com­mis­sion, which has the authority to approve med­i­cines for the Euro­pean …

• Pivotal Head-To-Head ENDEAVOR Study Shows Kyprolis and Dexamethasone Doubled Progression-Free Survival Versus Velcade® (Bortezomib) and Dexamethasone
• Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy
• Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval

Thousand Oaks, CA (Press Release) – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has approved the supple­mental New Drug Application (sNDA) of Kyprolis^® (car­filz­o­mib) for Injection in com­bi­na­tion with dexa­meth­a­sone or with lena­lido­mide plus dexa­meth­a­sone for the treat­ment of patients with re­lapsed or refractory multiple myeloma who have received one to three lines of ther­apy. The FDA also approved Kyprolis as a single agent for the treat­ment of patients with re­lapsed or refractory multiple …